cytokine release syndrome

News

Jeremy Skillington, Poolbeg's chief executive

Poolbeg expects first data for CRS drug in the summer

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

Oncology

Interview at ESMO 2025 with Liam Tremble

ESMO25: Transforming the cancer immunotherapy field, with Po...

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

Poolbeg expects first data for CRS drug in the summer

ESMO25: Transforming the cancer immunotherapy field, with Po...

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

Pfizer targets $2.5bn more in cost savings

Discover a new era of healthcare panel engagement: Grounded ...

cytokine release syndrome

Editor's Picks